Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2016 - 2025)

Lineage Cell Therapeutics' Cash & Equivalents history spans 16 years, with the latest figure at $46.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents changed 0.38% year-over-year to $46.0 million; the TTM value through Dec 2025 reached $46.0 million, changed 0.38%, while the annual FY2025 figure was $46.0 million, 0.38% changed from the prior year.
  • Cash & Equivalents reached $46.0 million in Q4 2025 per LCTX's latest filing, up from $32.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $78.1 million in Q1 2022 to a low of $15.5 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $43.9 million, with a median of $42.9 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 471.7% in 2021, then tumbled 80.21% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $55.7 million in 2021, then fell by 9.19% to $50.6 million in 2022, then tumbled by 40.87% to $29.9 million in 2023, then surged by 52.96% to $45.8 million in 2024, then rose by 0.38% to $46.0 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Cash & Equivalents are $46.0 million (Q4 2025), $32.2 million (Q3 2025), and $42.3 million (Q2 2025).